Analysts anticipate lower sales of blockbuster cancer drug Revlimid to squeeze Dr Reddy's margins for Q3, thereby dragging earnings growth.

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in January 2026, sparking concerns of a huge revenue void for the drugmaker.

2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose-limiting toxicity (DLT ...

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the decreasing revenue from Revlimid, which also affected margins. As Revlimid, ...